MCID: TRC022
MIFTS: 45

Tricuspid Valve Insufficiency

Categories: Cardiovascular diseases

Aliases & Classifications for Tricuspid Valve Insufficiency

MalaCards integrated aliases for Tricuspid Valve Insufficiency:

Name: Tricuspid Valve Insufficiency 12 43 15 71
Tricuspid Regurgitation 12 29 54 6 15
Tricuspid Valve Regurgitation 12
Tricuspid Incompetence 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4080
MeSH 43 D014262
NCIt 49 C50842
SNOMED-CT 67 111287006
UMLS 71 C0040961

Summaries for Tricuspid Valve Insufficiency

Disease Ontology : 12 A tricuspid valve disease that is characterized by failure of the heart's tricuspid valve to close properly during systole. As a result, with each heart beat, blood is pumped out from the right side of the heart in the opposite direction to normal.

MalaCards based summary : Tricuspid Valve Insufficiency, also known as tricuspid regurgitation, is related to atrioventricular block and chromosomal triplication. An important gene associated with Tricuspid Valve Insufficiency is PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11), and among its related pathways/superpathways is Development_Leptin signaling via JAK/STAT and MAPK cascades. The drugs Tolvaptan and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and lung, and related phenotypes are cardiovascular system and normal

Related Diseases for Tricuspid Valve Insufficiency

Diseases in the Tricuspid Valve Disease family:

Tricuspid Valve Insufficiency

Diseases related to Tricuspid Valve Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 421)
# Related Disease Score Top Affiliating Genes
1 atrioventricular block 31.4 NPPB CA5B ACE
2 chromosomal triplication 31.3 PAPPA CGB3
3 cardiogenic shock 31.2 NPPB CRP
4 pulmonary hypertension, primary, 1 31.0 NPPB EDN1 BMPR2
5 heart septal defect 30.9 ZIC3 PTPN11 F2 CA5B
6 hypoplastic left heart syndrome 30.8 ZIC3 NPPB ACE
7 endocarditis 30.7 F2 CRP ALB
8 chronic thromboembolic pulmonary hypertension 30.6 NPPB EDN1 CRP BMPR2
9 mobitz type ii atrioventricular block 30.6 CA5B ACE
10 aortic valve disease 2 30.6 NPPB CRP ARSL ACE
11 kawasaki disease 30.6 NPPB CRP ALB
12 sickle cell anemia 30.6 F2 EDN1 CRP ALB
13 right bundle branch block 30.6 NPPB CA5B BMPR2 ACE
14 rheumatic fever 30.6 NPPB ALB ACE
15 pericarditis 30.4 NPPB CRP ALB ACE
16 inferior myocardial infarction 30.4 NPPB CA5B
17 acute myocarditis 30.4 ZIC3 NPPB CRP ACE
18 left bundle branch hemiblock 30.4 NPPB CRP CA5B ACE
19 hemopneumothorax 30.4 F3 F2
20 systolic heart failure 30.4 NPPB EDN1 CRP ACE
21 pleural empyema 30.3 F2 CRP ALB
22 filariasis 30.3 EDN1 CRP ALB
23 hemopericardium 30.3 F3 F2
24 coronary stenosis 30.3 NPPB CRP ALB ACE
25 peripheral artery disease 30.2 NPPB F3 EDN1 CRP ACE
26 hepatopulmonary syndrome 30.2 EDN1 BMPR2 ALB
27 esophageal varix 30.2 F3 F2 ALB
28 congestive heart failure 30.2 PDE5A NPPB EDN1 CRP ALB ACE
29 cerebrovascular disease 30.2 NPPB F2 CRP ACE
30 disseminated intravascular coagulation 30.1 F3 F2 CRP
31 sleep apnea 30.0 NPPB EDN1 CRP ALB ACE
32 pulmonary edema 30.0 NPPB F2 EDN1 CRP ACE
33 lung disease 30.0 NPPB F3 EDN1 CRP ALB ACE
34 pulmonary disease, chronic obstructive 30.0 PDE5A NPPB CRP ALB ACE
35 liver cirrhosis 30.0 F3 F2 EDN1 ALB
36 mitral valve disease 30.0 PDZK1IP1 NPPB F3 F2 CRP CPB1
37 bilirubin metabolic disorder 30.0 F3 F2 CRP ALB
38 thrombocytosis 30.0 F3 F2 CRP ALB
39 eclampsia 29.9 PAPPA F2 EDN1 ALB ACE
40 arteries, anomalies of 29.9 F3 EDN1 CRP ALB ACE
41 acute myocardial infarction 29.8 PAPPA NPPB F3 EDN1 CRP ACE
42 patent ductus arteriosus 1 29.8 ZIC3 PTPN11 PDZK1IP1 NPPB EDN1 CRP
43 heart valve disease 29.7 PDZK1IP1 NPPB F2 CRP CPB1 ARSL
44 constrictive pericarditis 29.7 ZIC3 WBP2NL NPPB CRP ARSL ALB
45 tetralogy of fallot 29.7 ZIC3 PTPN11 NPPB EDN1 CRP CA5B
46 mitral valve insufficiency 29.6 ZIC3 PDZK1IP1 NPPB F2 CRP CPB1
47 atrial fibrillation 29.6 NPPB F3 F2 CRP ALB ACE
48 cardiac tamponade 29.6 NPPB F3 F2 CRP ALB ACE
49 mitral valve stenosis 29.6 WBP2NL PDZK1IP1 NPPB F3 F2 CRP
50 kidney disease 29.6 NPPB F3 EDN1 CRP ALB ACE

Graphical network of the top 20 diseases related to Tricuspid Valve Insufficiency:



Diseases related to Tricuspid Valve Insufficiency

Symptoms & Phenotypes for Tricuspid Valve Insufficiency

MGI Mouse Phenotypes related to Tricuspid Valve Insufficiency:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.65 ACE ALB BMPR2 CRP EDN1 F2
2 normal MP:0002873 9.28 ALB BMPR2 EDN1 F2 F3 PAPPA

Drugs & Therapeutics for Tricuspid Valve Insufficiency

Drugs for Tricuspid Valve Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tolvaptan Approved Phase 4 150683-30-0 216237
2
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Ezetimibe Approved Phase 4 163222-33-1 150311
6
Atorvastatin Approved Phase 4 134523-00-5 60823
7
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
8
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
9
Metolazone Approved Phase 4 17560-51-9 4170
10 Sodium Potassium Chloride Symporter Inhibitors Phase 4
11 Vasopressins Phase 4
12 Arginine Vasopressin Phase 4
13 Torsemide Phase 4
14 Anesthetics, Local Phase 4
15 Hypolipidemic Agents Phase 4
16 Anticholesteremic Agents Phase 4
17 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
18 Lipid Regulating Agents Phase 4
19 Antimetabolites Phase 4
20 diuretics Phase 4
21
Nitroglycerin Approved, Investigational Phase 3 55-63-0 4510
22
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
23
Milrinone Approved Phase 3 78415-72-2 4197
24
Empagliflozin Approved Phase 3 864070-44-0
25
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
26
Angiotensin II Approved, Investigational Phase 3 4474-91-3, 11128-99-7, 68521-88-0 172198
27
Valsartan Approved, Investigational Phase 3 137862-53-4 60846
28
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
29 Kava Approved, Investigational, Nutraceutical Phase 2, Phase 3 9000-38-8
30 Natriuretic Peptide, Brain Phase 3
31 Phosphodiesterase Inhibitors Phase 2, Phase 3
32 Phosphodiesterase 5 Inhibitors Phase 2, Phase 3
33 Citrate Phase 2, Phase 3
34 Sildenafil Citrate Phase 2, Phase 3 171599-83-0
35 Cardiotonic Agents Phase 3
36 Phosphodiesterase 3 Inhibitors Phase 3
37 Platelet Aggregation Inhibitors Phase 3
38 Antihypertensive Agents Phase 3
39 Hormones Phase 3
40 Adrenergic alpha-Antagonists Phase 3
41 Adrenergic Agents Phase 3
42 Antioxidants Phase 3
43 Adrenergic Antagonists Phase 3
44 Sodium-Glucose Transporter 2 Inhibitors Phase 3
45 Vasodilator Agents Phase 3
46 Hypoglycemic Agents Phase 3
47 Adrenergic beta-Antagonists Phase 3
48 Neurotransmitter Agents Phase 3
49 Protective Agents Phase 3
50 Adrenergic alpha-1 Receptor Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 129)
# Name Status NCT ID Phase Drugs
1 The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement Completed NCT02644616 Phase 4 tolvaptan+torasemide;placebo+torasemide
2 The Effect of Cardiac Pacing Leads on Tricuspid Regurgitation Completed NCT01093001 Phase 4
3 Peripheral Nerve Blocks for Major Lower Extremity Amputations Recruiting NCT03174782 Phase 4 Bupivacaine;Saline Solution
4 Assessment of the Effects of Long-term Lipid-lowering Therapy on Parameters of Electrical Myocardial Heterogeneity, Myocardial Deformation Characteristics, Vascular Rigidity, and Quality of Life in Patients With Primary STEMI or NSTEMI Recruiting NCT04347434 Phase 4 Atorvastatin 80mg
5 Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation HOVER Trial Active, not recruiting NCT02339974 Phase 4
6 Effect of Protocolized Diuretic Strategy on Clinical Outcomes and Health-related Quality of Life in Cardiorenal Failure: A Randomized Trial Terminated NCT01921829 Phase 4 Protocolized Diuretic Strategy
7 Trial of Right Ventricular Versus Modified Blalock-Taussig Shunt in Infants With Single Ventricle Defect Undergoing Staged Reconstruction (A Trial Conducted by the Pediatric Heart Network) Completed NCT00115934 Phase 3
8 Postoperative Analgesia After Cardiac Surgery - A Double-Blind, Prospective and Randomized Comparison of Wound Infiltration With Liposomal Bupivacaine and Bupivacaine Hydrochloride Completed NCT03270514 Phase 3 Exparel Injectable Product;Bupivacaine Hydrochloride
9 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Hemodynamic and Clinical Effects of Natrecor (Nesiritide) Compared With Nitroglycerin Therapy for Symptomatic Decompensated CHF, The VMAC Trial: Vasodilation in the Management of Acute Congestive Heart Failure Completed NCT00270374 Phase 3 nesiritide
10 Pulmonary Hypertension Secondary to Heart Failure With Preserved Systolic Function: a Target of Phosphodiesterase - 5 Inhibition in a 1- Year Duration Study Completed NCT01156636 Phase 2, Phase 3 Sildenafil;Placebo
11 Comparative Effects of Brief Inhaled Milrinone Versus Intravenous Milrinone on Pulmonary Arterial Pressure in Patients Undergoing Mitral Valve Surgery Completed NCT01621971 Phase 3 inhaled milrinone;intravenous milrinone
12 Multicenter, Randomized, 2 x 2 Factorial, Phase 3 Study to Assess the Efficacy of Carvedilol and Empagliflozin on Improvement of Right Ventricular Remodeling in Patients With Severe Functional Tricuspid Regurgitation Not yet recruiting NCT04345796 Phase 3 Carvedilol+Empagliflozin;Carvedilol;Empagliflozin;Placebo
13 PRospectIve Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in PatiEnts With Heart Failure and Preserved Ejection Fraction Not yet recruiting NCT04128891 Phase 3 Sacubitril-Valsartan
14 Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve Terminated NCT02387697 Phase 2, Phase 3
15 Catheter Denervation of Pulmonary Arteries in The Treatment of Idiopathic (PAH) & Secondary Pulmonary Hypertension (PH) Unknown status NCT02403908 Phase 1
16 Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™ Completed NCT02098200 Phase 1
17 A Randomized, Placebo-controlled, Study to Evaluate the Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers Completed NCT01673555 Phase 1 GSK1278863;Placebo
18 The Role of Endothelin-1 in Sickle Cell Disease Completed NCT02712346 Phase 1 Ambrisentan;Placebo
19 An Exploratory, 3-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects With World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated With Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in Subjects With WHO Group 3 PH Associated With Idiopathic Pulmonary Fibrosis (IPF) on LTOT (Part 2 and Part 3) Completed NCT02267655 Phase 1 inhaled Nitric Oxide - 30 mcg/kg IBW/hr;inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr;inhaled nitric oxide 75 mcg/kg IBW/hr
20 Autologous Cardiac Stem Cell Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study. Recruiting NCT03406884 Phase 1
21 Comparison of Rigid Annuloplasty Ring With a Band in the Correction of Secondary Tricuspid Insufficiency Unknown status NCT03144024
22 The Impact of Right Ventricular Pacing on Tricuspid Regurgitation Unknown status NCT00419354
23 Comparison Between Outcomes Of Ring And Suture Annuloplasty For Functional Tricuspid Regurgitation In Rheumatic Mitral Valve Diseases Unknown status NCT02721524
24 Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) for Symptomatic Chronic Functional Tricuspid Regurgitation Unknown status NCT02574650
25 Prospective, Randomized Evaluation of Prophylactic Tricuspid Valve Annuloplasty in Patients Undergoing Mitral Valve Surgery Unknown status NCT01580436
26 Behaviour of Tricuspid Valve Regurgitation in Volume and/or Pressure Loaded Right Heart Unknown status NCT01444222
27 Transcatheter Treatment of Severe Tricuspid Regurgitation Using the MitraClip System Unknown status NCT02863549
28 Multi-centre Randomised Trial Investigating the Effect of PROphylactic triCuspID Annuloplasty in Patients With Dilated Tricuspid Annulus on Tricuspid Regurgitation Progression, Right Ventricular Remodeling and Functional Outcomes Unknown status NCT03129737
29 Left Ventricular Pacing to Prevent Iatrogenic Tricuspid Regurgitation Caused by Conventional Right Ventricular Pacing: a Pilot Study Unknown status NCT02314897
30 Long-term Outcome After Isolated Tricuspid Valve Repair Unknown status NCT01537458
31 Is There a Correlation Between the Pulmonary Artery Pressure and the Acceleration of the Flow in the Pulmonary Artery Evaluated by Transesophageal Echocardiography (TOE) ? Unknown status NCT01947257
32 Evaluation of the Characteristics, Prevalence and Prognosis of Pulmonary Hypertension in Adult Patients With Sickle Cell Disease: Study ETENDARD. Unknown status NCT00434902
33 Comparison Between Right and Left Ventricular Systolic Dysfunction as a Risk Factors for AKI in Critical Care Patients Unknown status NCT03369561
34 Non Invasive Detection of Acute Rejection by Circulating microRNAs in Cardiac Transplantation: a Multicenter Prospective Study Unknown status NCT02672683
35 Comparison of Right Ventricular Outflow Tract Gradient Under Anaesthesia With Post-operative Gradient in Patients Undergoing Tetralogy of Fallot Repair Unknown status NCT03234582
36 Noninvasive Diagnosis of Pulmonary Hypertension Using Three-dimensional Interventricular Septal Curvedness From Cardiac Magnetic Resonance Images Unknown status NCT02790918
37 A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy Unknown status NCT03214757
38 Cardiac Output and Central Venous Oxygen Saturation Monitoring Using the Vigileo FloTrac Sensor Versus Conventional Thermodilution Method Using the Pulmonary Artery Catheter: A Prospective Study Unknown status NCT00641290
39 Study of the Safety of Flexible Bronchoscopy in Patients With Pulmonary Hypertension Unknown status NCT00986869
40 Diastolic Dysfunction in Sickle Cell Disease During Vaso-occlusive Crisis Unknown status NCT01683968
41 Quantitative Assessment of Right Ventricular Strain Utilizing Cardiac Magnetic Resonance Imaging: Development of an Optimal Measure of Treatment Response Following Catheter-directed Interventions on Sub-massive Pulmonary Embolism. Unknown status NCT03341208
42 Right Ventricular Function After Mitral Valve Replacement in Rheumatic Heart Disease Patients With Pulmonary Hypertension: Short Term Follow up Unknown status NCT03549052
43 Italian Multicenter PROject on Echo Assessment of Left VEntricular (IMPROVE) Dyssynchrony Study Unknown status NCT00646243
44 The Institute of Cardiovascular Surgery Completed NCT01246141
45 A Prospective Randomized Trial of Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Mitral Operation Completed NCT01246947
46 Contour 3D®/TriAd® Tricuspid Annuloplasty Ring Post-Market Clinical Trial Completed NCT01585779
47 Prognostic Value of Early Postoperative Right Ventricular Systolic Function in Patients With Isolated Severe Tricuspid Regurgitation Completed NCT01203137
48 Evaluation of Mitral and Tricuspid Regurgitation: Cardiovascular Magnetic Resonance Imaging Versus Echocardiographic Doppler Color Flow Mapping of the Vena Contracta Completed NCT01504880
49 Prophylactic Tricuspid Annuloplasty During Mitral Valve Surgery Completed NCT03604484
50 TRI-REPAIR: TrIcuspid Regurgitation RePAIr With CaRdioband Transcatheter System Completed NCT02981953

Search NIH Clinical Center for Tricuspid Valve Insufficiency

Cochrane evidence based reviews: tricuspid valve insufficiency

Genetic Tests for Tricuspid Valve Insufficiency

Genetic tests related to Tricuspid Valve Insufficiency:

# Genetic test Affiliating Genes
1 Tricuspid Regurgitation 29

Anatomical Context for Tricuspid Valve Insufficiency

MalaCards organs/tissues related to Tricuspid Valve Insufficiency:

40
Heart, Liver, Lung, Testes, Brain, Bone, Whole Blood

Publications for Tricuspid Valve Insufficiency

Articles related to Tricuspid Valve Insufficiency:

(show top 50) (show all 5470)
# Title Authors PMID Year
1
Prenatal sonographic features of fetuses in trisomy 13 pregnancies. IV. 54 61
20466286 2010
2
Clinical utility of B-type natriuretic peptide for estimating left ventricular filling pressures in unselected elderly patients undergoing diagnostic coronary angiography. 61 54
20197576 2010
3
Application of classic heart failure definitions of asymptomatic and symptomatic ventricular dysfunction and heart failure symptoms with preserved ejection fraction to patients with systemic right ventricles. 54 61
19616677 2009
4
Elevated serum cobalamin in patients with decompensated biventricular failure. 61 54
19011393 2008
5
Right heart dysfunction assessed with echography, B-type natriuretic peptide and cardiopulmonary test in patients with chronic heart failure. 61 54
18545065 2008
6
B-type natriuretic peptide in patients with systemic right ventricle. 54 61
17934262 2008
7
Assessment of factors affecting plasma BNP levels in patients with chronic atrial fibrillation and preserved left ventricular systolic function. 54 61
16959341 2007
8
Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks. 61 54
16388509 2006
9
[Feasibility of cardiopulmonary rehabilitation in patients with idiopathic pulmonary arterial hypertension treated with intravenous prostacyclin infusion therapy]. 61 54
16320975 2005
10
Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. 54 61
15520111 2004
11
Usefulness of B-type natriuretic peptide levels in predicting hemodynamic perturbations after heart transplantation despite preserved left ventricular systolic function. 54 61
12480042 2002
12
Effect of membrane insertion for tricuspid regurgitation using immersed-boundary lattice Boltzmann method. 61
32146209 2020
13
Quantitative assessment of effective regurgitant orifice: impact on risk stratification, and cut-off for severe and torrential tricuspid regurgitation grade. 61
31642895 2020
14
Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study. 61
32243618 2020
15
Anesthetic Considerations for Transcatheter Tricuspid Valve Repair. 61
31761655 2020
16
Use of Lifetech™ Konar-MF, a device for both perimembranous and muscular ventricular septal defects: A multicentre study. 61
32122701 2020
17
Serial changes of tricuspid regurgitation after anatomic repair for congenitally corrected transposition. 61
32048707 2020
18
Mid-diastolic tricuspid regurgitation: a novel echocardiographic marker for an athlete's heart? 61
32142122 2020
19
Perinatal diagnosis and management of early-onset Marfan syndrome: case report and systematic review. 61
30652519 2020
20
Assessment and management of heart failure in the systemic right ventricle. 61
31970551 2020
21
Correlation between changes in brain natriuretic peptide and echocardiographic features in persistent pulmonary hypertension of newborn. 61
30995876 2020
22
Associations between functional tricuspid regurgitation and long-term outcomes for patients with pulmonary hypertension. 61
32236906 2020
23
Understanding tricuspid valve remodelling in atrial fibrillation using three-dimensional echocardiography. 61
32372089 2020
24
Alterations to cardiac morphology and function among high-altitude workers: a retrospective cohort study. 61
32269133 2020
25
Long-term atrial arrhythmias incidence after heart transplantation. 61
32331908 2020
26
Relapse of aortopulmonary window 41 years after patch closure. 61
31750891 2020
27
Percutaneous Treatment of a Four-Leaf Clover Valve Using the MitraClip Technology. 61
32407678 2020
28
LV pacing as an alternative option to conventional RV pacing in a patient with tricuspid valve replacement. 61
32528584 2020
29
Diagnostic analysis of abnormal increase of PASP in fetus in middle- and late-stage pregnancy by color Doppler echocardiography. 61
32160003 2020
30
Transcatheter edge-to-edge tricuspid repair for recurrence of valvular regurgitation after left ventricular assist device and tricuspid ring implantation. 61
32144947 2020
31
MSCT-fluoroscopy fusion imaging for guidance in percutaneous bicaval valve implantation for transcatheter treatment of tricuspid regurgitation. 61
32533155 2020
32
Burden of Tricuspid Regurgitation in Patients Undergoing Coronary Artery Bypass Grafting. 61
32497644 2020
33
Transcatheter tricuspid annuloplasty with the Cardioband device to treat severe functional tricuspid regurgitation. 61
31974069 2020
34
Quantification of tricuspid regurgitation area by 3-dimensional color Doppler echocardiography considering different clinical settings. 61
32562588 2020
35
Impact of inferior caval valve implantation on severity of tricuspid regurgitation and right heart function. 61
32536000 2020
36
The Quest to Better Quantitate Tricuspid Regurgitation. 61
32563634 2020
37
Liver stiffness value obtained by point shear wave elastography is significantly related with atrial septal defect size. 61
32558650 2020
38
From Other Journals: A Review of Recent Articles in Pediatric Cardiology. 61
32572547 2020
39
Prognostic implications of tricuspid annular plane systolic excursion/pulmonary arterial systolic pressure ratio in septic shock patients. 61
32532300 2020
40
Dextrocardia, situs solitus, inlet ventricular septal defect (VSD), and iatrogenic tricuspid regurgitation (TR)-A surgical perspective. 61
32349171 2020
41
Prognostic role of moderate functional tricuspid regurgitation in length of hospitalization in patients undergoing isolated coronary artery bypass grafting. 61
32200479 2020
42
Comparison of different imaging modalities for the quantification of tricuspid valve geometry and regurgitation: a retrospective, single-center study. 61
32337374 2020
43
Isolated tricuspid valve regurgitation: old concepts, new insights and innovation. 61
32073432 2020
44
A Meta-analysis and Systematic Review of Valvular Heart Disease in Systemic Lupus Erythematosus and Its Association With Antiphospholipid Antibodies. 61
32558678 2020
45
Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review. 61
32540411 2020
46
Ebstein anomaly combined with unique pulmonary venous abnormality in a 9-month-old child. 61
32484126 2020
47
Pulmonary hypertension due to left heart disease: diagnostic value of pulmonary artery distensibility. 61
32548647 2020
48
Impact of Preoperative Measurement of Right Heart Chambers in the Evaluation of Pulmonary Hypertension Following Aortic Valve Replacement. 61
31958443 2020
49
The Assessment of Myocardial Strain by Cardiac Imaging in Healthy Infants with Acute Bronchiolitis: A Systematic Review and Meta-Analysis. 61
32521769 2020
50
The tricuspid annular plane systolic excursion to systolic pulmonary artery pressure index: Association with all-cause mortality in patients with moderate or severe tricuspid regurgitation. 61
32512064 2020

Variations for Tricuspid Valve Insufficiency

ClinVar genetic disease variations for Tricuspid Valve Insufficiency:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PTPN11 NM_002834.5(PTPN11):c.184T>G (p.Tyr62Asp)SNV Pathogenic 13329 rs121918460 12:112888168-112888168 12:112450364-112450364
2 46;XX;ins(5;6)(p13;p24p25)dnTranslocation Pathogenic 267851
3 MYH11 NM_002474.3(MYH11):c.4360G>C (p.Asp1454His)SNV Likely pathogenic 374162 rs1057518938 16:15818023-15818023 16:15724166-15724166
4 GATA4 NM_002052.5(GATA4):c.1273G>A (p.Asp425Asn)SNV Conflicting interpretations of pathogenicity 9034 rs56208331 8:11615928-11615928 8:11758419-11758419
5 46;XX;inv(14)(q24.1q32.1)dninversion Uncertain significance 267889

Expression for Tricuspid Valve Insufficiency

Search GEO for disease gene expression data for Tricuspid Valve Insufficiency.

Pathways for Tricuspid Valve Insufficiency

Pathways related to Tricuspid Valve Insufficiency according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.28 PTPN11 EDN1 CRP

GO Terms for Tricuspid Valve Insufficiency

Cellular components related to Tricuspid Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 PAPPA NPPB F3 F2 EDN1 CRP
2 extracellular space GO:0005615 9.36 PAPPA NPPB F3 F2 EDN1 CRP

Biological processes related to Tricuspid Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of renal sodium excretion GO:0035815 9.4 NPPB EDN1
2 positive regulation of urine volume GO:0035810 9.37 NPPB EDN1
3 negative regulation of systemic arterial blood pressure GO:0003085 9.32 NPPB BMPR2
4 negative regulation of hormone secretion GO:0046888 9.26 PTPN11 EDN1
5 positive regulation of hormone secretion GO:0046887 9.16 PTPN11 EDN1
6 body fluid secretion GO:0007589 8.96 NPPB EDN1
7 regulation of blood pressure GO:0008217 8.92 NPPB MC3R EDN1 ACE

Sources for Tricuspid Valve Insufficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....